Viruses are formidable adversaries, possessing an uncanny ability to mutate into stronger forms each time one strain was defeated, necessitating new interventions
Alynlam Pharmaceuticals recently made headlines when they announced the results of a revolutionary RNA interference therapy capable of controlling high blood pressure.
Announcing two licensing deals with Swiss pharma giant Novartis AG, Shanghai-based Argo Biopharmaceutical Co. Ltd. said on Jan. 7 that it stands to gain up to $4.165 billion for two of its cardiovascular assets combined. Marking the “first significant overseas out-licensing transaction in the RNAi field from a Chinese biotech company,” the deal includes an up-front payment of $185 million from Novartis to Argo.
Last week marked the historic Food and Drug Administration approval of the first CRISPR therapy. Five other Nobel-winning breakthroughs have led to recent new medicines.
On September 7, 2023, Alnylam Pharmaceuticals announced positive topline data from the phase 2 KARDIA-1 trial of zilbesiran in the treatment of hypertension.